DexCom (NASDAQ:DXCM) Director Sells 2,000 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the sale, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. The trade was a 3.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Down 0.4%

Shares of NASDAQ:DXCM traded down $0.37 during midday trading on Tuesday, reaching $86.94. The company had a trading volume of 5,993,713 shares, compared to its average volume of 5,297,699. The stock has a market capitalization of $32.81 billion, a P/E ratio of 34.36, a PEG ratio of 1.36 and a beta of 1.41. The stock’s fifty day moving average price is $73.44 and its 200-day moving average price is $69.31. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.85.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. Equities research analysts expect that DexCom, Inc. will post 2.6 earnings per share for the current fiscal year.

Institutional Trading of DexCom

Institutional investors have recently made changes to their positions in the stock. Reflection Asset Management acquired a new stake in DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom during the 1st quarter valued at about $25,000. MCF Advisors LLC acquired a new position in shares of DexCom in the 4th quarter worth approximately $32,000. Wellington Grp LLC grew its stake in shares of DexCom by 778.7% in the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new stake in shares of DexCom in the 4th quarter worth approximately $36,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent research reports. Royal Bank Of Canada raised their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price on the stock. Robert W. Baird set a $105.00 price target on DexCom in a research report on Friday. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, Benchmark boosted their price objective on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.